Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Short Interest Update

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the recipient of a large increase in short interest in the month of August. As of August 31st, there was short interest totaling 27,645 shares, an increase of 172,681.2% from the August 15th total of 16 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average daily volume of 474,592 shares, the short-interest ratio is presently 0.1 days.

Oncotelic Therapeutics Trading Up 5.3%

Shares of Oncotelic Therapeutics stock opened at $0.03 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 0.08 and a current ratio of 0.08. The company has a market capitalization of $14.43 million, a P/E ratio of 0.05 and a beta of -0.24. Oncotelic Therapeutics has a 1 year low of $0.01 and a 1 year high of $0.11. The company’s fifty day moving average is $0.04 and its two-hundred day moving average is $0.04.

Oncotelic Therapeutics Company Profile

Oncotelic Therapeutics is a clinical‐stage biotechnology company dedicated to the development of novel oncolytic virotherapy and diagnostic platforms for cancer treatment. The company’s lead therapeutic candidate, telomelysin (OBP‐301), is an oncolytic adenovirus engineered to selectively replicate in telomerase‐positive tumor cells, offering a targeted approach to destroying cancerous tissue while sparing healthy cells. In addition to its therapeutic pipeline, Oncotelic markets TelomeScan, a proprietary diagnostic assay designed to detect and enumerate viable circulating tumor cells by exploiting telomerase activity.

Originally founded with technology licensed from Japanese research institutions, Oncotelic has established collaborative relationships in both the United States and Asia to advance its clinical and commercial programs.